 | • レポートコード：TMR2008084 • 出版社/出版日：Transparency Market Research / 2020年6月 • レポート形態：英文、PDF、238ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは神経障害性疼痛治療の世界市場について調査・分析し、序文、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、薬物クラス別（抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド）分析、疾患別（糖尿病性神経障害、帯状疱疹後神経痛、がん関連痛み、脊髄損傷、その他）分析、投与経路別（経口、局所、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを含め、以下の構成でご提供いたします。 ・序文 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・神経障害性疼痛治療の世界市場：薬物クラス別（抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド） ・神経障害性疼痛治療の世界市場：疾患別（糖尿病性神経障害、帯状疱疹後神経痛、がん関連痛み、脊髄損傷、その他） ・神経障害性疼痛治療の世界市場：投与経路別（経口、局所、その他） ・神経障害性疼痛治療の世界市場：流通チャンネル別（病院薬局、小売薬局、オンライン薬局） ・神経障害性疼痛治療の世界市場：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Neuropathic Pain Therapeutics Market – Scope of the Report
TMR’s report on the global neuropathic pain therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global neuropathic pain therapeutics market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neuropathic pain therapeutics market from 2020 to 2030.
The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global neuropathic pain therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neuropathic pain therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global neuropathic pain therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neuropathic pain therapeutics market.
The report also delves into the competition landscape of the global neuropathic pain therapeutics market. Key players operating in the global neuropathic pain therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neuropathic pain therapeutics market that have been profiled in this report.
Key Questions Answered in Neuropathic Pain Therapeutics Market Report
What is the sales/revenue generated by neuropathic pain drugs across all regions during the forecast period?
What are the opportunities in the global neuropathic therapeutics pain market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which indication segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Neuropathic Pain Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global neuropathic pain therapeutics market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global neuropathic pain therapeutics market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neuropathic pain therapeutics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neuropathic Pain Therapeutics Market
4. Market Overview
4.1. Introduction & Overview
4.2. Product Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018–2030
5. Market Outlook
5.1. Pipeline Analysis
5.2. Treatment Guidelines
5.3. COVID-19 Pandemics Impact on Industry
6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
6.2.1. Anticonvulsants
6.2.2. Antidepressants
6.2.2.1. Tricyclic Antidepressants
6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
6.2.3. NSAIDs
6.2.4. Opioids
6.2.5. Steroids
6.2.6. Others
6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class
7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018–2030
7.2.1. Diabetic Neuropathy
7.2.2. Post-herpetic Neuralgia
7.2.3. Cancer-related Pain
7.2.4. Spinal Cord Injury
7.2.5. Others
7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication
8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018–2030
8.2.1. Oral
8.2.2. Topical
8.2.3. Others
8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration
9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel
10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region
11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
11.2.1. Anticonvulsants
11.2.2. Antidepressants
11.2.2.1. Tricyclic Antidepressants
11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
11.2.3. NSAIDs
11.2.4. Opioids
11.2.5. Steroids
11.2.6. Others
11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
11.3.1. Diabetic Neuropathy
11.3.2. Post-herpetic Neuralgia
11.3.3. Cancer-related Pain
11.3.4. Spinal Cord Injury
11.3.5. Others
11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
11.4.1. Oral
11.4.2. Topical
11.4.3. Others
11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
11.6.1. U.S.
11.6.2. Canada
11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
12.2.1. Anticonvulsants
12.2.2. Antidepressants
12.2.2.1. Tricyclic Antidepressants
12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
12.2.3. NSAIDs
12.2.4. Opioids
12.2.5. Steroids
12.2.6. Others
12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
12.3.1. Diabetic Neuropathy
12.3.2. Post-herpetic Neuralgia
12.3.3. Cancer-related Pain
12.3.4. Spinal Cord Injury
12.3.5. Others
12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
12.4.1. Oral
12.4.2. Topical
12.4.3. Others
12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
13.2.1. Anticonvulsants
13.2.2. Antidepressants
13.2.2.1. Tricyclic Antidepressants
13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
13.2.3. NSAIDs
13.2.4. Opioids
13.2.5. Steroids
13.2.6. Others
13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
13.3.1. Diabetic Neuropathy
13.3.2. Post-herpetic Neuralgia
13.3.3. Cancer-related Pain
13.3.4. Spinal Cord Injury
13.3.5. Others
13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
13.4.1. Oral
13.4.2. Topical
13.4.3. Others
13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
14.2.1. Anticonvulsants
14.2.2. Antidepressants
14.2.2.1. Tricyclic Antidepressants
14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
14.2.3. NSAIDs
14.2.4. Opioids
14.2.5. Steroids
14.2.6. Others
14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
14.3.1. Diabetic Neuropathy
14.3.2. Post-herpetic Neuralgia
14.3.3. Cancer-related Pain
14.3.4. Spinal Cord Injury
14.3.5. Others
14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
14.4.1. Oral
14.4.2. Topical
14.4.3. Others
14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
15.2.1. Anticonvulsants
15.2.2. Antidepressants
15.2.2.1. Tricyclic Antidepressants
15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
15.2.3. NSAIDs
15.2.4. Opioids
15.2.5. Steroids
15.2.6. Others
15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
15.3.1. Diabetic Neuropathy
15.3.2. Post-herpetic Neuralgia
15.3.3. Cancer-related Pain
15.3.4. Spinal Cord Injury
15.3.5. Others
15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
15.4.1. Oral
15.4.2. Topical
15.4.3. Others
15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Competition Matrix
16.2. Market Share Analysis, by Company, 2019
16.3. Company Profiles
16.3.1. Novartis AG
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. GlaxoSmithKline plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. AstraZeneca
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Pfizer, Inc.
16.3.4.1. Company Overview (HQ, Business Segments)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Eli Lilly and Company
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Mallinckrodt Pharmaceuticals
16.3.6.1. Company Overview (HQ, Business Segments)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Johnson & Johnson
16.3.7.1. Company Overview (HQ, Business Segments)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Abbott
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Endo Pharmaceuticals, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Teva Pharmaceutical Industries Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Merck & Co., Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
List of TablesTable 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030